229 related articles for article (PubMed ID: 33397584)
1. Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival.
Al-Ahmadi A; Ardeshir-Larijani F; Fu P; Cao S; Lipka MB; Dowlati A; Bruno DS
Clin Lung Cancer; 2021 Jan; 22(1):16-22.e1. PubMed ID: 33397584
[TBL] [Abstract][Full Text] [Related]
2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
3. Association between race and survival of patients with non--small-cell lung cancer in the United States veterans affairs population.
Ganti AK; Subbiah SP; Kessinger A; Gonsalves WI; Silberstein PT; Loberiza FR
Clin Lung Cancer; 2014 Mar; 15(2):152-8. PubMed ID: 24361249
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
5. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
7. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer.
Arrieta O; Aviles-Salas A; Orozco-Morales M; Hernández-Pedro N; Cardona AF; Cabrera-Miranda L; Barrios-Bernal P; Soca-Chafre G; Cruz-Rico G; Peña-Torres ML; Moncada-Claudio G; Ramirez-Tirado LA
Cancer Med; 2020 Apr; 9(7):2390-2402. PubMed ID: 32043750
[TBL] [Abstract][Full Text] [Related]
8. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
[TBL] [Abstract][Full Text] [Related]
9. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
[TBL] [Abstract][Full Text] [Related]
10. Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.
Cheng H; Hosgood HD; Deng L; Ye K; Su C; Sharma J; Yang Y; Halmos B; Perez-Soler R
Clin Lung Cancer; 2020 Mar; 21(2):177-185. PubMed ID: 31420240
[TBL] [Abstract][Full Text] [Related]
11. Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States.
Ramalingam S; Dinan MA; Crawford J
J Thorac Oncol; 2018 Dec; 13(12):1842-1850. PubMed ID: 30312680
[TBL] [Abstract][Full Text] [Related]
12. Racial and Ethnic Disparities in Lung Adenocarcinoma Survival: A Competing-Risk Model.
Wu X; Wang Y; Lin X; Wang Z; Xu J; Lv W; Hu J
Clin Lung Cancer; 2020 May; 21(3):e171-e181. PubMed ID: 31787547
[TBL] [Abstract][Full Text] [Related]
13. Disparate outcomes in nonsmall cell lung cancer by immigration status.
Chau B; Ituarte PH; Shinde A; Li R; Vazquez J; Glaser S; Massarelli E; Salgia R; Erhunmwunsee L; Ashing K; Amini A
Cancer Med; 2021 Apr; 10(8):2660-2667. PubMed ID: 33734614
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
[TBL] [Abstract][Full Text] [Related]
15. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
Bergqvist M; Christensen HN; Wiklund F; Bergström S
Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
[TBL] [Abstract][Full Text] [Related]
16. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
17. Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.
Begnaud A; Yang P; Robichaux C; Rubin N; Kratzke R; Melzer A; Aliferis C; Jacobson P
Clin Lung Cancer; 2020 May; 21(3):e164-e168. PubMed ID: 31759888
[TBL] [Abstract][Full Text] [Related]
18. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
Lee K; Kim D; Yoon S; Lee DH; Kim SW
Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
